Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
MAPK14 1432 CHEMBL564912 CHEMBL564912 DrugBank 17139284, 17016423
MAPK14 1432 CHEMBL87277 CHEMBL87277 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 CHEMBL94417 CHEMBL94417 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 CHEMBL29641 CHEMBL29641 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 TALMAPIMOD CHEMBL514201 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
MAPK14 1432 VX-702 CHEMBL1090090 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank
MAPK14 1432 VX-745 CHEMBL119385 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 10592235
MAPK14 1432 CHEMBL492265 CHEMBL492265 DrugBank 10592235
MAPK14 1432 CHEMBL522579 CHEMBL522579 DrugBank 10592235
MAPK14 1432 CHEMBL380373 CHEMBL380373 DrugBank 10592235
MAPK14 1432 CHEMBL410668 CHEMBL410668 DrugBank 10592235
MAPK14 1432 AZD-6703 CHEMBL2031465 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 LOSMAPIMOD CHEMBL1088752 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, TTD
MAPK14 1432 CHEMBL1951415 CHEMBL1951415 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 RALIMETINIB CHEMBL2364626 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 ARRY-797 CHEMBL1088750 inhibitor TdgClinicalTrial, ChemblInteractions
MAPK14 1432 GSK-610677 CHEMBL3544968 inhibitor ChemblInteractions, TTD
MAPK14 1432 RALIMETINIB MESYLATE CHEMBL2364627 ClearityFoundationClinicalTrial
MAPK14 1432 LEO-15520 CHEMBL3545074 inhibitor ChemblInteractions
MAPK14 1432 RWJ-67657 CHEMBL190333 inhibitor ChemblInteractions
MAPK14 1432 CHEMBL305178 CHEMBL305178 DrugBank 17139284, 17016423
MAPK14 1432 CHEMBL193156 CHEMBL193156 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 SB-220025 CHEMBL274064 inhibitor GuideToPharmacologyInteractions, DrugBank 17139284, 17016423, 10592235
MAPK14 1432 CHEMBL194322 CHEMBL194322 DrugBank 10592235
MAPK14 1432 CHEMBL199237 CHEMBL199237 DrugBank 10592235
MAPK14 1432 CHEMBL273158 CHEMBL273158 DrugBank 10592235
MAPK14 1432 CHEMBL478649 CHEMBL478649 DrugBank 10592235
MAPK14 1432 SD-0006 CHEMBL1090173 inhibitor ChemblInteractions, DrugBank 10592235
MAPK14 1432 CHEMBL379760 CHEMBL379760 DrugBank 10592235
MAPK14 1432 CHEMBL559401 CHEMBL559401 DrugBank 10592235
MAPK14 1432 CHEMBL371491 CHEMBL371491 DrugBank 10592235
MAPK14 1432 CHEMBL96741 CHEMBL96741 DrugBank 10592235
MAPK14 1432 CHEMBL1236539 CHEMBL1236539 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 Acumapimod CHEMBL3545226 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 BMS-582949 CHEMBL1230065 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 SB-202190 CHEMBL278041 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 TAK-715 CHEMBL363648 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 EPOETIN BETA CHEMBL2109092 NCI 10590051
MAPK14 1432 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 12919900
MAPK14 1432 AZD-7624 CHEMBL9960 inhibitor ChemblInteractions
MAPK14 1432 CHEMBL85860 CHEMBL85860 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 2-CHLOROPHENOL CHEMBL108877 DrugBank 17139284, 17016423
MAPK14 1432 CHEMBL197277 CHEMBL197277 DrugBank 10592235
MAPK14 1432 CHEMBL522387 CHEMBL522387 DrugBank 10592235
MAPK14 1432 CHEMBL252128 CHEMBL252128 DrugBank 10592235
MAPK14 1432 CHEMBL258202 CHEMBL258202 DrugBank 10592235
MAPK14 1432 GW607117X CHEMBL270164 DrugBank 10592235
MAPK14 1432 PH-797804 CHEMBL1088751 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 10592235
MAPK14 1432 CHEMBL191598 CHEMBL191598 DrugBank 10592235
MAPK14 1432 CHEMBL365776 CHEMBL365776 DrugBank 10592235
MAPK14 1432 CHEMBL425616 CHEMBL425616 DrugBank 10592235
MAPK14 1432 PF-03715455 CHEMBL1938400 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
MAPK14 1432 CHEMBL306380 CHEMBL306380 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 METHOXSALEN CHEMBL416 NCI 15711930
MAPK14 1432 DOXYCYCLINE CHEMBL1433 NCI 16643899
MAPK14 1432 PIRFENIDONE CHEMBL1256391 TdgClinicalTrial
MAPK14 1432 Pexmetinib CHEMBL3545297 inhibitor TdgClinicalTrial, ChemblInteractions
MAPK14 1432 RAVIDASVIR CHEMBL3121849 NCI 15313431
MAPK14 1432 VASOPRESSIN CHEMBL373742 NCI 10679516, 11029753
MAPK14 1432 SC-80036 CHEMBL3544930 inhibitor ChemblInteractions
MAPK14 1432 SCIO-323 CHEMBL1614702 inhibitor ChemblInteractions
MAPK14 1432 TA-5493 CHEMBL3545201 inhibitor ChemblInteractions
MAPK14 1432 PG-760564 CHEMBL3545398 inhibitor ChemblInteractions
MAPK14 1432 FX-005 CHEMBL3545216 inhibitor ChemblInteractions
MAPK14 1432 AMG-548 CHEMBL585902 inhibitor ChemblInteractions
MAPK14 1432 AVE-9940 CHEMBL3545117 inhibitor ChemblInteractions
MAPK14 1432 CHEMBL194009 CHEMBL194009 DrugBank 17139284, 17016423, 10592235
MAPK14 1432 DORAMAPIMOD CHEMBL103667 inhibitor GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 17139284, 17016423
MAPK14 1432 CHEMBL590753 CHEMBL590753 DrugBank 10592235
MAPK14 1432 KC-706 CHEMBL3545282 inhibitor TdgClinicalTrial, ChemblInteractions, DrugBank
MAPK14 1432 CHEMBL237127 CHEMBL237127 DrugBank 10592235
MAPK14 1432 CHEMBL195450 CHEMBL195450 DrugBank 10592235
MAPK14 1432 CHEMBL195393 CHEMBL195393 DrugBank 10592235
MAPK14 1432 CHEMBL494072 CHEMBL494072 DrugBank 10592235
MAPK14 1432 CHEMBL257341 CHEMBL257341 DrugBank 10592235
MAPK14 1432 Ro-3201195 CHEMBL203567 inhibitor ChemblInteractions, DrugBank 10592235
MAPK14 1432 SB-203580 CHEMBL10 inhibitor GuideToPharmacologyInteractions, DrugBank 10592235
MAPK14 1432 CHEMBL193264 CHEMBL193264 DrugBank 10592235
MAPK14 1432 PROPOXYPHENE CHEMBL1213351 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 DILMAPIMOD CHEMBL2103838 inhibitor TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TTD
MAPK14 1432 CHEMBL313417 CHEMBL313417 inhibitor GuideToPharmacologyInteractions
MAPK14 1432 SEMAPIMOD CHEMBL2107779 inhibitor TdgClinicalTrial, ChemblInteractions
MAPK14 1432 R-1487 (CHEMBL1766582) CHEMBL1766582 inhibitor ChemblInteractions
MAPK14 1432 PS-516895 CHEMBL3545139 inhibitor ChemblInteractions
MAPK14 1432 SB-85635 CHEMBL3545384 inhibitor ChemblInteractions
MAPK14 1432 PAMAPIMOD CHEMBL1090089 inhibitor ChemblInteractions
MAPK14 1432 LY-3007113 CHEMBL3544998 inhibitor ChemblInteractions
MAPK14 1432 DOXORUBICIN CHEMBL53463 NCI 15557793, 16905201
MAPK14 1432 2-METHOXYESTRADIOL CHEMBL299613 NCI 17012370
MAPK14 1432 HYDROGEN PEROXIDE CHEMBL71595 NCI 9706151
MAPK14 1432 MORPHINE CHEMBL70 NCI 11937560
MAPK14 1432 RESVERATROL CHEMBL165 NCI 16525036
MAPK14 1432 SULINDAC SULFIDE CHEMBL18797 NCI 15657353
MAPK14 1432 LITHIUM CHEMBL2146126 NCI 12558976
MAPK14 1432 HALOPERIDOL CHEMBL54 NCI 11080184

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
MAPK14 rs3804454 G bevacizumab efficacy no Neovascular age-related macular degeneration. Response was based on the optical coherence tomography (OCT) metric of total retinal thickness (TRT). Change in TRT was calculated between baseline and after 3, 6, 9 or 12 months of treatment, depending on the patient. Eyes with TRT changes >= the 75th percentile were classified as responders; those with changes <= the 25th percentile were classified as nonresponders. Cases = responders; controls = nonresponders. p-value was Bonferroni-corrected for 482 tests (uncorrected p-value = 0.01). Please note alleles have been complemented to the plus chromosomal strand. Allele G is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to allele T. 24070809 1184165275